Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High – Still a Buy?

Posted by Geri Gentry on Sep 16th, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $38.42 and last traded at $38.5010, with a volume of 862605 shares traded. The stock had previously closed at $37.09.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Potential tax refund: The Delhi High Court ordered India’s tax department to refund ₹783 crore to Teva Israel in connection with a payment related to the Ranbaxy acquisition. The ruling could provide a meaningful cash inflow, although the timing and any further legal or administrative steps remain uncertain. Delhi High Court tax refund article
Positive Sentiment: Direct NYSE trading begins: Teva’s ordinary shares now trade directly on the New York Stock Exchange, a structural milestone intended to improve access for U.S. investors, potentially support liquidity, and increase the company’s visibility as it pursues its growth strategy. Teva NYSE listing announcement
Positive Sentiment: Balance-sheet and strategy focus: Recent coverage highlighted a major debt refinancing and management’s efforts to pivot Teva toward growth. Refinancing could improve maturity management and financial flexibility, while CEO Richard Francis has been promoting the company’s next phase to investors. Teva NYSE trading and refinancing article
Neutral Sentiment: Presentations at the Morgan Stanley healthcare conference and the CEO’s market interview may reinforce investor confidence in Teva’s pipeline and strategy, but they do not represent a new financial forecast or confirmed earnings catalyst. Teva Morgan Stanley conference transcript

Analyst Ratings Changes

Several brokerages recently commented on TEVA. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings downgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Ten research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $43.10.

Read Our Latest Report on TEVA

Teva Pharmaceutical Industries Stock Up 1.1%

The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The stock’s fifty day moving average price is $35.06 and its two-hundred day moving average price is $33.44.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The business had revenue of $4.14 billion for the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $1,098,060,000. WCM Investment Management LLC raised its position in Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the period. Castle Hook Partners LP acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth about $82,013,000. Finally, Capital World Investors bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $73,687,000. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.